Price History
Feb 9, 2026 — May 24, 2026Investment Snapshot
- Trading 145% above Graham Number — above intrinsic value estimate
- Piotroski F-Score 6/9 — moderate financial health
- Strong ROE of 82.6% with 28.6% net margin
Zoetis Inc. Class A Common Stock (ZTS) is a Healthcare company operating in Pharmaceutical Preparations, listed on the NYSE , with a market capitalisation of $34.1 billion . Key value metrics: P/E ratio 12.8, P/B ratio 10.54, Piotroski F-Score 6 out of 9 (moderate financial health) .
Value Score
Key Metrics
Current vs 5-Year Average
Based on 5 years of SEC filingsRevenue & Net Income
Financial Statements
| Metric | FY22 | FY23 | FY24 |
|---|---|---|---|
| Revenue | $X.XB | $X.XB | $X.XB |
| Gross Profit | $X.XB | $X.XB | $X.XB |
| Operating Income | $X.XB | $X.XB | $X.XB |
| Net Income | $X.XB | $X.XB | $X.XB |
| EBITDA | $X.XB | $X.XB | $X.XB |
| Total Assets | $X.XB | $X.XB | $X.XB |
| Total Liabilities | $X.XB | $X.XB | $X.XB |
Zoetis Inc. Class A Common Stock — Fundamental Analysis Summary
Zoetis Inc. Class A Common Stock (ZTS) is currently trading 145% above its Graham Number of $33.25, suggesting the market price exceeds Benjamin Graham's intrinsic value estimate. The stock carries a reasonable trailing P/E ratio of 12.8x.
On financial health, ZTS shows a moderate Piotroski F-Score of 6/9, and strong return on equity of 82.6% (sector average: -20.6%), and high leverage with a debt-to-equity ratio of 2.80.
StockPik's composite Value Score for ZTS is 69/100 — an above-average value rating. The score is built from ten fundamental signals: P/E, P/B, PEG ratio, P/S ratio, return on equity, gross margin, debt-to-equity, current ratio, dividend yield, and Piotroski F-Score.
ZTS shows revenue growing at 2% year-over-year, with earnings growing at 8%.
ZTS pays a modest dividend yield of 1.9%.